SCHEMBL7109748

SCHEMBL7109748

CC(N)COc1ccc2c(c1)[nH]c1ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 7/20 0.54
CTSV O60911 1/20 0.50
CTSL P07711 1/20 0.50
MAOA P21397 1/20 0.47
GABRP O00591 5/20 0.47
GABRD O14764 5/20 0.47
GABRA1 P14867 5/20 0.47
GABRB1 P18505 5/20 0.47
GABRG2 P18507 5/20 0.47
GABRB3 P28472 5/20 0.47
GABRA5 P31644 5/20 0.47
GABRA3 P34903 5/20 0.47
GABRA2 P47869 5/20 0.47
GABRB2 P47870 5/20 0.47
GABRA4 P48169 5/20 0.47
GABRE P78334 5/20 0.47
GABRA6 Q16445 5/20 0.47
GABRG1 Q8N1C3 5/20 0.47
GABRG3 Q99928 5/20 0.47
GABRQ Q9UN88 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7109746 1.00 KIF11 (0.54) KIF11CTSVCTSLMAOAGABRP
SCHEMBL8182735 0.80 CTSV (0.48) KIF11CTSVCTSLMAOAGABRA1
SCHEMBL14027323 0.80 KIF11 (0.51) KIF11CTSVCTSLMAOAGABRP
SCHEMBL7810203 0.80 CTSV (0.48) KIF11CTSVCTSLMAOAGABRA1
SCHEMBL6009648 0.80 KIF11 (0.61) KIF11CTSVCTSLGABRPGABRD
SCHEMBL7809148 0.78 ADRB2 (0.64) ALDH1A1MAPT
SCHEMBL12722429 0.77 GABRP (0.58) KIF11CTSVCTSLMAOAGABRP
SCHEMBL16790723 0.77 GABRP (0.61) KIF11CTSVCTSLGABRPGABRD
SCHEMBL7108868 0.77 KIF11 (0.54) KIF11CTSVCTSLMAOAGABRP
SCHEMBL7247905 0.76 KIF11 (0.61) KIF11CTSVCTSLGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882707-B1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME ASAHI CHEMICAL IND (JP) 2003-10-08 EP disclosed
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-07-24 US disclosed
US-6545053-B1 Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-04-08 US disclosed
US-6187809-B1 BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2001-02-13 US disclosed
US-6037362-A CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2000-03-14 US disclosed
EP-0882707-A1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ADRB3, MC2R, NR3C1 KIF11 4828/4885CTSV 4729/4885CTSL 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.